CRISPR Gene Editing in 2024: Curing Sickle Cell Disease

Welcome to a new era of medical science. The historic FDA approval of Casgevy marks the very first time a CRISPR-based therapy has been cleared for human use. This medical breakthrough offers hope to thousands of patients suffering from sickle cell disease, fundamentally changing how we approach genetic disorders in 2024.

The Historic FDA Approval of Casgevy

On December 8, 2023, the U.S. Food and Drug Administration made history by approving Casgevy, a gene-editing therapy designed specifically to treat sickle cell disease. Developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics, this treatment transitioned from a laboratory concept to a prescribed medicine in just over a decade.

As we move through 2024, specialized medical centers across the United States are actively preparing to administer this treatment. The FDA specifically approved Casgevy for patients aged 12 and older who suffer from recurrent vaso-occlusive crises. These crises are severe pain episodes caused when misshapen red blood cells block blood flow, causing excruciating pain and organ damage. Sickle cell disease affects approximately 100,000 Americans, predominantly those of African and Hispanic descent.

How Casgevy Rewrites Genetic Code

To understand why Casgevy is so revolutionary, you need to look at how it works at a microscopic level. Sickle cell disease is caused by a single mutation in the gene that tells the body how to make hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. This specific mutation causes the cells to form a hard, sticky “C” shape (a sickle).

Casgevy uses CRISPR/Cas9 technology to edit the patient’s own DNA. Scientists discovered years ago that humans produce a different type of hemoglobin before birth, known as fetal hemoglobin. Shortly after a baby is born, a specific gene called BCL11A turns off the production of fetal hemoglobin and switches the body over to adult hemoglobin. In sickle cell patients, this adult hemoglobin is defective.

Casgevy works by cutting the DNA in the BCL11A gene. This precise edit disables the gene, effectively removing the biological stop sign. The body then resumes making fetal hemoglobin. Because fetal hemoglobin does not sickle, it can effectively carry oxygen throughout the body and prevent the pain crises.

The Demanding Patient Journey

While the science sounds almost magical, the actual treatment process is grueling. Casgevy is not a simple pill you can pick up at a local pharmacy. It is a highly personalized procedure that takes several months to complete.

• Stem Cell Collection: First, doctors give the patient medication to release stem cells from the bone marrow into the bloodstream. A machine then filters the blood to collect these precious cells. This initial step can take multiple hospital visits.
• Laboratory Editing: The collected stem cells are shipped to a specialized Vertex Pharmaceuticals manufacturing facility. Scientists spend several weeks using CRISPR to precisely edit the BCL11A gene in these cells.
• Chemotherapy (Conditioning): While the cells are being edited in the lab, the patient must undergo high-dose chemotherapy using a drug called busulfan. This step clears out the remaining defective bone marrow to make room for the newly edited cells. This is often the hardest part of the process, bringing severe side effects like hair loss, nausea, and a highly weakened immune system.
• The Infusion: Finally, the edited stem cells are infused back into the patient through an IV. The patient must stay in the hospital for four to six weeks while the new cells settle into the bone marrow and begin producing healthy red blood cells.

Pricing and Accessibility in 2024

The arrival of a genetic cure comes with a massive price tag. Vertex Pharmaceuticals set the wholesale price of Casgevy at $2.2 million per patient.

While $2.2 million sounds astronomical, health economists point out that sickle cell disease is incredibly expensive to manage over a lifetime. Frequent hospital stays, emergency room visits for pain crises, and regular blood transfusions cost the healthcare system millions of dollars per patient. A one-time treatment that eliminates these crises could actually save money in the long run.

Insurance coverage remains a significant hurdle in 2024. Because many sickle cell patients rely on Medicaid, state governments are currently negotiating with Vertex and the federal government to figure out payment models. Some states are exploring outcomes-based agreements, where the state only pays the full price if the treatment continues to work for the patient years down the line.

It is also worth noting that Casgevy is not the only gene therapy approved for sickle cell disease. On the exact same day in December 2023, the FDA approved Lyfgenia, a treatment made by Bluebird Bio. Lyfgenia uses a different method involving a harmless virus to insert a modified gene, rather than using CRISPR editing. Bluebird Bio priced Lyfgenia at $3.1 million.

What This Means for the Future of Medicine

The success of Casgevy paves the way for a whole new generation of genetic medicines. If scientists can safely edit the BCL11A gene to treat sickle cell disease, they can potentially target other severe genetic disorders.

In fact, the progress has already continued. On January 16, 2024, the FDA expanded the approval of Casgevy to treat transfusion-dependent beta-thalassemia, another severe blood disorder. Medical researchers are now looking at how CRISPR might treat muscular dystrophy, cystic fibrosis, and even certain types of cancer.

Companies like Intellia Therapeutics and Editas Medicine are currently running clinical trials targeting diseases of the liver and eyes. The 2024 rollout of Casgevy serves as the ultimate test case for manufacturing, delivering, and paying for CRISPR therapies. Medical centers are busy building the specialized clean rooms and training the staff required to handle these sensitive cellular products. The lessons learned from treating sickle cell patients this year will directly impact how quickly we can bring other genetic cures to the general public.

Frequently Asked Questions

How much does the Casgevy treatment cost? Vertex Pharmaceuticals priced Casgevy at $2.2 million for a single course of treatment. This high cost covers the highly complex, personalized laboratory process required to edit a patient’s individual stem cells, as well as the decades of research required to bring the drug to market.

Is Casgevy a permanent cure for sickle cell disease? Doctors are hesitant to use the word “cure” permanently until patients have been monitored for a lifetime, but the data is incredibly promising. In clinical trials, 29 out of 31 patients treated with Casgevy did not experience a single severe pain crisis for at least 12 months after the infusion. The treatment is designed to last a lifetime.

Who is eligible to receive Casgevy in 2024? Currently, the FDA has approved Casgevy for patients who are 12 years of age and older. The patient must have sickle cell disease with a history of recurrent vaso-occlusive crises (severe pain episodes). Furthermore, patients must be physically healthy enough to withstand the intensive busulfan chemotherapy required before the edited cells are infused back into their bodies.